1918 related articles for article (PubMed ID: 16730617)
21. Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder.
Haab F; Stewart L; Dwyer P
Eur Urol; 2004 Apr; 45(4):420-9; discussion 429. PubMed ID: 15041104
[TBL] [Abstract][Full Text] [Related]
22. Impact of solifenacin on quality of life, medical care use, work productivity, and health utility in the elderly: an exploratory subgroup analysis.
Zinner N; Noe L; Rasouliyan L; Marshall T; Runken MC; Seifeldin R
Am J Geriatr Pharmacother; 2009 Dec; 7(6):373-82. PubMed ID: 20129258
[TBL] [Abstract][Full Text] [Related]
23. Tolerability of 5 mg solifenacin once daily versus 5 mg oxybutynin immediate release 3 times daily: results of the VECTOR trial.
Herschorn S; Stothers L; Carlson K; Egerdie B; Gajewski JB; Pommerville P; Schulz J; Radomski S; Drutz H; Barkin J; Paradiso-Hardy F
J Urol; 2010 May; 183(5):1892-8. PubMed ID: 20303119
[TBL] [Abstract][Full Text] [Related]
24. Solifenacin for overactive bladder: patient-reported outcomes from a large placebo-controlled trial.
Toglia MR; Serels SR; Laramée C; Karram MM; Nandy IM; Andoh M; Seifeldin R; Forero-Schwanhaeuser S
Postgrad Med; 2009 Sep; 121(5):151-8. PubMed ID: 19820284
[TBL] [Abstract][Full Text] [Related]
25. Safety and tolerability of solifenacin add-on therapy to α-blocker treated men with residual urgency and frequency.
Kaplan SA; McCammon K; Fincher R; Fakhoury A; He W
J Urol; 2013 Jan; 189(1 Suppl):S129-34. PubMed ID: 23234618
[TBL] [Abstract][Full Text] [Related]
26. Treatment of overactive bladder in the older patient: pooled analysis of three phase III studies of darifenacin, an M3 selective receptor antagonist.
Foote J; Glavind K; Kralidis G; Wyndaele JJ
Eur Urol; 2005 Sep; 48(3):471-7. PubMed ID: 15990219
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of simplified bladder training in patients with overactive bladder receiving a solifenacin flexible-dose regimen: results from a randomized study.
Mattiasson A; Masala A; Morton R; Bolodeoku J;
BJU Int; 2010 Apr; 105(8):1126-35. PubMed ID: 19818077
[TBL] [Abstract][Full Text] [Related]
28. Tolterodine extended release is efficacious in continent and incontinent subjects with overactive bladder.
Rovner ES; Rackley R; Nitti VW; Wang JT; Guan Z;
Urology; 2008 Sep; 72(3):488-93. PubMed ID: 18639327
[TBL] [Abstract][Full Text] [Related]
29. A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder.
Chapple C; Steers W; Norton P; Millard R; Kralidis G; Glavind K; Abrams P
BJU Int; 2005 May; 95(7):993-1001. PubMed ID: 15839920
[TBL] [Abstract][Full Text] [Related]
30. Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia.
Kaplan SA; Roehrborn CG; Dmochowski R; Rovner ES; Wang JT; Guan Z
Urology; 2006 Aug; 68(2):328-32. PubMed ID: 16904446
[TBL] [Abstract][Full Text] [Related]
31. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.
Herschorn S; Swift S; Guan Z; Carlsson M; Morrow JD; Brodsky M; Gong J
BJU Int; 2010 Jan; 105(1):58-66. PubMed ID: 20132103
[TBL] [Abstract][Full Text] [Related]
32. Treatment outcomes in the STAR study: a subanalysis of solifenacin 5 mg and tolterodine ER 4 mg.
Chapple CR; Fianu-Jonsson A; Indig M; Khullar V; Rosa J; Scarpa RM; Mistry A; Wright DM; Bolodeoku J;
Eur Urol; 2007 Oct; 52(4):1195-203. PubMed ID: 17574730
[TBL] [Abstract][Full Text] [Related]
33. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms.
Kaplan SA; Roehrborn CG; Gong J; Sun F; Guan Z
BJU Int; 2012 Jun; 109(12):1831-40. PubMed ID: 21966995
[TBL] [Abstract][Full Text] [Related]
34. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.
Rogers RG; Bachmann G; Scarpero H; Jumadilova Z; Sun F; Morrow JD; Guan Z; Bavendam T
Curr Med Res Opin; 2009 Sep; 25(9):2159-65. PubMed ID: 19601704
[TBL] [Abstract][Full Text] [Related]
35. A randomized double-blind placebo-controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome.
Robinson D; Cardozo L; Terpstra G; Bolodeoku J;
BJU Int; 2007 Oct; 100(4):840-5. PubMed ID: 17822465
[TBL] [Abstract][Full Text] [Related]
36. Solifenacin treatment for overactive bladder in Hispanic patients: patient-reported symptom bother and quality of life outcomes from the VESIcare Open-Label Trial.
Capo' JP; Laramée C; Lucente V; Fakhoury A; Forero-Schwanhaeuser S
Int J Clin Pract; 2008 Jan; 62(1):39-46. PubMed ID: 18036164
[TBL] [Abstract][Full Text] [Related]
37. Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial.
Khullar V; Hill S; Laval KU; Schiøtz HA; Jonas U; Versi E
Urology; 2004 Aug; 64(2):269-74; discussion 274-5. PubMed ID: 15302476
[TBL] [Abstract][Full Text] [Related]
38. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers.
Chapple C; Herschorn S; Abrams P; Sun F; Brodsky M; Guan Z
Eur Urol; 2009 Sep; 56(3):534-41. PubMed ID: 19070418
[TBL] [Abstract][Full Text] [Related]
39. Nighttime dosing with tolterodine reduces overactive bladder-related nocturnal micturitions in patients with overactive bladder and nocturia.
Rackley R; Weiss JP; Rovner ES; Wang JT; Guan Z;
Urology; 2006 Apr; 67(4):731-6; discussion 736. PubMed ID: 16618562
[TBL] [Abstract][Full Text] [Related]
40. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial.
Chapple CR; Martinez-Garcia R; Selvaggi L; Toozs-Hobson P; Warnack W; Drogendijk T; Wright DM; Bolodeoku J;
Eur Urol; 2005 Sep; 48(3):464-70. PubMed ID: 15990220
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]